董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Colin Hill | 男 | Director | 48 | 20.50万美元 | 未持股 | 2021-03-08 |
| David Simmons | 男 | Chairman and Chief Executive Officer | 56 | 341.75万美元 | 未持股 | 2021-03-08 |
| Joe Bress | 男 | Director | 38 | 未披露 | 未持股 | 2021-03-08 |
| Stephen Ensley | 男 | Director | 36 | 未披露 | 未持股 | 2021-03-08 |
| P. Hunter Philbrick | 男 | Director | 41 | 未披露 | 未持股 | 2021-03-08 |
| Stephen H. Wise | 男 | Director | 48 | 未披露 | 未持股 | 2021-03-08 |
| Maria Teresa Hilado | 女 | Director | 56 | 23.25万美元 | 未持股 | 2021-03-08 |
| Allen R. Thorpe | 男 | Director | 50 | 未披露 | 未持股 | 2021-03-08 |
| Jeffrey B. Kindler | 男 | Director | 65 | 21.75万美元 | 未持股 | 2021-03-08 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David Simmons | 男 | Chairman and Chief Executive Officer | 56 | 341.75万美元 | 未持股 | 2021-03-08 |
| Christopher G. Scully | 男 | Executive Vice President and Chief Financial Officer, Treasurer and Assistant Secretary | 50 | 100.48万美元 | 未持股 | 2021-03-08 |
| Glen Donovan | 男 | Chief Accounting Officer | 47 | 未披露 | 未持股 | 2021-03-08 |
| Anshul Thakral | 男 | Executive Vice President, Chief Commercial Officer and President of Evidera | 43 | 113.41万美元 | 未持股 | 2021-03-08 |
| B. Judd Hartman | 男 | Executive Vice President, Chief Administrative Officer | 57 | 104.42万美元 | 未持股 | 2021-03-08 |
| Christopher Fikry | 男 | Executive Vice President, Global Laboratory Services | 44 | 未披露 | 未持股 | 2021-03-08 |
| Ronald Garrow | 男 | Executive Vice President and Chief Human Resource Officer | 57 | 未披露 | 未持股 | 2021-03-08 |
| Karen Kaucic | 女 | Executive Vice President, Chief Medical Officer | 61 | 未披露 | 未持股 | 2021-03-08 |
| Julia James | 女 | Executive Vice President, General Counsel and Secretary | 46 | 未披露 | 未持股 | 2021-03-08 |
| William J. Sharbaugh | 男 | Chief Operating Officer | 58 | 111.88万美元 | 未持股 | 2021-03-08 |
| 姜大卫 | 男 | Executive Vice President of Global Clinical Development | 52 | 78.89万美元 | 未持股 | 2021-03-08 |
董事简历
中英对照 | 中文 | 英文- Colin Hill
-
Colin Hill于2000年共同创立了数据分析公司GNS梦百合Inc.，并一直担任其首席执行官。希尔先生还是GNS梦百合公司的母公司Gene Network Sciences，Inc.的董事长。Hill先生目前在BioTelemetry Inc.的董事会任职。Beat，一家远程医疗技术公司。他也是TMED（转化医学:the Elizabeth Kauffman Institute）的创始董事会成员，这是一个致力于推进个性化医疗的非营利基金会。
Colin Hill co-founded GNS Healthcare Inc., a data analytics company, in 2000 and has since served as its Chief Executive Officer. Mr. Hill is also the Chairman of Gene Network Sciences, Inc., the parent company of GNS Healthcare Inc. Mr. Hill currently serves on the board of directors of Biotelemetry Inc. BEAT, a remote medical technology company. He is also a founding board member of TMed (Transforming Medicine: The Elizabeth Kauffman Institute), a non-profit foundation dedicated to the advancement of personalized medicine. - Colin Hill于2000年共同创立了数据分析公司GNS梦百合Inc.，并一直担任其首席执行官。希尔先生还是GNS梦百合公司的母公司Gene Network Sciences，Inc.的董事长。Hill先生目前在BioTelemetry Inc.的董事会任职。Beat，一家远程医疗技术公司。他也是TMED（转化医学:the Elizabeth Kauffman Institute）的创始董事会成员，这是一个致力于推进个性化医疗的非营利基金会。
- Colin Hill co-founded GNS Healthcare Inc., a data analytics company, in 2000 and has since served as its Chief Executive Officer. Mr. Hill is also the Chairman of Gene Network Sciences, Inc., the parent company of GNS Healthcare Inc. Mr. Hill currently serves on the board of directors of Biotelemetry Inc. BEAT, a remote medical technology company. He is also a founding board member of TMed (Transforming Medicine: The Elizabeth Kauffman Institute), a non-profit foundation dedicated to the advancement of personalized medicine.
- David Simmons
-
David Simmons，目前担任创新心血管医疗技术公司Cordis的董事会成员。除了担任PPD董事长外，Simmons之前的董事会服务还包括Curia Global， Inc. （Albany Molecular Research Inc.， 2021年之前），Launch Therapeutics, Inc., Medline Industries, Inc.和Owens & Minor， Inc.的任期。他目前还担任Abingworth LLP（一家领先的生命科学风险投资公司）的高级顾问。他在Carnegie Mellon大学获得应用数学和工业管理学士学位。
David Simmons,currently serves on the board of directors of Cordis, an innovative cardiovascular medical technology company. In addition to serving as Chairman of PPD, Simmons' previous board service includes tenures at Curia Global, Inc. (Albany Molecular Research Inc. prior to 2021), Launch Therapeutics, Inc., Medline Industries, Inc. and Owens & Minor, Inc. He also currently serves as a senior advisor to Abingworth LLP, a leading life sciences venture capital firm. Simmons earned his bachelor's degree in applied mathematics and industrial management from Carnegie Mellon University. - David Simmons，目前担任创新心血管医疗技术公司Cordis的董事会成员。除了担任PPD董事长外，Simmons之前的董事会服务还包括Curia Global， Inc. （Albany Molecular Research Inc.， 2021年之前），Launch Therapeutics, Inc., Medline Industries, Inc.和Owens & Minor， Inc.的任期。他目前还担任Abingworth LLP（一家领先的生命科学风险投资公司）的高级顾问。他在Carnegie Mellon大学获得应用数学和工业管理学士学位。
- David Simmons,currently serves on the board of directors of Cordis, an innovative cardiovascular medical technology company. In addition to serving as Chairman of PPD, Simmons' previous board service includes tenures at Curia Global, Inc. (Albany Molecular Research Inc. prior to 2021), Launch Therapeutics, Inc., Medline Industries, Inc. and Owens & Minor, Inc. He also currently serves as a senior advisor to Abingworth LLP, a leading life sciences venture capital firm. Simmons earned his bachelor's degree in applied mathematics and industrial management from Carnegie Mellon University.
- Joe Bress
-
Joe Bress目前担任凯雷投资集团（Carlyle Group）的董事总经理，该公司是一家跨国私募股权公司，他于2007年7月加入该公司。他目前担任Welldynerx公司（一家独立的药房福利管理公司）、Albany Molecular Research公司（一家合同研究和药品制造组织）、CorroHealth公司（一家为梦百合公司提供商业服务的公司）、Millicent Pharma公司（一家制药公司）和Trinetx公司的董事，服务于生命科学行业的真实世界数据技术业务。在Carlyle之前，Bress先生从2005年到2007年在UBS的并购集团工作。
Joe Bress currently serves as a Managing Director at The Carlyle Group, a multinational private equity firm, which he joined in July 2007. He currently serves on the board of directors of WellDyneRx, an independent pharmacy benefit manager, Albany Molecular Research, a contract research and drug manufacturing organization, CorroHealth, a business service provider for healthcare companies, Millicent Pharma, a pharmaceutical company, and TriNetX, a real world data technology business serving the life sciences industry. Prior to Carlyle, Mr. Bress worked in the Mergers and Acquisitions group at UBS from 2005 to 2007. - Joe Bress目前担任凯雷投资集团（Carlyle Group）的董事总经理，该公司是一家跨国私募股权公司，他于2007年7月加入该公司。他目前担任Welldynerx公司（一家独立的药房福利管理公司）、Albany Molecular Research公司（一家合同研究和药品制造组织）、CorroHealth公司（一家为梦百合公司提供商业服务的公司）、Millicent Pharma公司（一家制药公司）和Trinetx公司的董事，服务于生命科学行业的真实世界数据技术业务。在Carlyle之前，Bress先生从2005年到2007年在UBS的并购集团工作。
- Joe Bress currently serves as a Managing Director at The Carlyle Group, a multinational private equity firm, which he joined in July 2007. He currently serves on the board of directors of WellDyneRx, an independent pharmacy benefit manager, Albany Molecular Research, a contract research and drug manufacturing organization, CorroHealth, a business service provider for healthcare companies, Millicent Pharma, a pharmaceutical company, and TriNetX, a real world data technology business serving the life sciences industry. Prior to Carlyle, Mr. Bress worked in the Mergers and Acquisitions group at UBS from 2005 to 2007.
- Stephen Ensley
-
Stephen Ensley目前担任跨国私募股权公司Hellman&Friedman的合伙人。2009年加入Hellman&Friedman之前，Ensley从2007年到2009年担任J.P.Morgan并购集团投资银行家。他目前任职于Genesys Telecommunications Laboratories，Inc.（客户参与软件供应商）的运营委员会，以及Checkmarx公司（应用安全测试市场的市场领导者）的董事会。Ensley先生曾是医生服务提供商Sheridan梦百合，Inc.和汽车数据提供商Carproof的董事。
Stephen Ensley currently serves as a Partner of Hellman & Friedman, a multinational private equity firm. Prior to joining Hellman & Friedman in 2009 Mr. Ensley worked as an investment banker in the Mergers and Acquisitions group at J.P. Morgan from 2007 to 2009. He currently serves on the operating committee of Genesys Telecommunications Laboratories, Inc., a customer engagement software provider, and the board of directors of Checkmarx, a market leader in the application security testing market. Mr. Ensley was formerly a director of Sheridan Healthcare, Inc., a provider of physician services, and CarProof, an automotive data provider. - Stephen Ensley目前担任跨国私募股权公司Hellman&Friedman的合伙人。2009年加入Hellman&Friedman之前，Ensley从2007年到2009年担任J.P.Morgan并购集团投资银行家。他目前任职于Genesys Telecommunications Laboratories，Inc.（客户参与软件供应商）的运营委员会，以及Checkmarx公司（应用安全测试市场的市场领导者）的董事会。Ensley先生曾是医生服务提供商Sheridan梦百合，Inc.和汽车数据提供商Carproof的董事。
- Stephen Ensley currently serves as a Partner of Hellman & Friedman, a multinational private equity firm. Prior to joining Hellman & Friedman in 2009 Mr. Ensley worked as an investment banker in the Mergers and Acquisitions group at J.P. Morgan from 2007 to 2009. He currently serves on the operating committee of Genesys Telecommunications Laboratories, Inc., a customer engagement software provider, and the board of directors of Checkmarx, a market leader in the application security testing market. Mr. Ensley was formerly a director of Sheridan Healthcare, Inc., a provider of physician services, and CarProof, an automotive data provider.
- P. Hunter Philbrick
-
P.Hunter Philbrick自2013年1月起担任跨国私募股权公司Hellman&Friedman的合伙人。在2003年加入Hellman&Friedman之前，Philbrick先生曾在摩根士丹利&Co.的合并、收购和重组以及一般工业部门担任投资银行家，他目前担任Hub International Limited的董事会成员，全球保险经纪公司Multiplan Corporation（MPLN），一家梦百合成本管理服务提供商，以及Vantage Group Holdings Ltd.，一家商业财产和意外伤害保险运营商。Philbrick先生曾担任独立的梦百合技术平台Change HealthcareInc.（CHNG）（前EMDEON）、住宅财产保险公司Geovera Insurance Holdings Ltd.和技术风险、收益和综合商业解决方案提供商Sedgwick Inc.的董事。
P. Hunter Philbrick has served as a Partner at Hellman & Friedman, a multinational private equity firm, since January 2013. Prior to joining Hellman & Friedman in 2003 Mr. Philbrick worked as an investment banker in the mergers, acquisitions and restructuring and general industrial departments of Morgan Stanley & Co MS. He currently serves as a member of the board of directors of HUB International Limited, a global insurance brokerage firm, MultiPlan Corporation (MPLN), a healthcare cost management service provider, and Vantage Group Holdings Ltd., a commercial property and casualty insurance carrier. Mr. Philbrick was formerly a director of Change Healthcare Inc. (CHNG) (formerly Emdeon), an independent healthcare technology platform, GeoVera Insurance Holdings Ltd., a residential property insurance company, and Sedgwick Inc., a provider of technology-enabled risk, benefits and integrated business solutions. - P.Hunter Philbrick自2013年1月起担任跨国私募股权公司Hellman&Friedman的合伙人。在2003年加入Hellman&Friedman之前，Philbrick先生曾在摩根士丹利&Co.的合并、收购和重组以及一般工业部门担任投资银行家，他目前担任Hub International Limited的董事会成员，全球保险经纪公司Multiplan Corporation（MPLN），一家梦百合成本管理服务提供商，以及Vantage Group Holdings Ltd.，一家商业财产和意外伤害保险运营商。Philbrick先生曾担任独立的梦百合技术平台Change HealthcareInc.（CHNG）（前EMDEON）、住宅财产保险公司Geovera Insurance Holdings Ltd.和技术风险、收益和综合商业解决方案提供商Sedgwick Inc.的董事。
- P. Hunter Philbrick has served as a Partner at Hellman & Friedman, a multinational private equity firm, since January 2013. Prior to joining Hellman & Friedman in 2003 Mr. Philbrick worked as an investment banker in the mergers, acquisitions and restructuring and general industrial departments of Morgan Stanley & Co MS. He currently serves as a member of the board of directors of HUB International Limited, a global insurance brokerage firm, MultiPlan Corporation (MPLN), a healthcare cost management service provider, and Vantage Group Holdings Ltd., a commercial property and casualty insurance carrier. Mr. Philbrick was formerly a director of Change Healthcare Inc. (CHNG) (formerly Emdeon), an independent healthcare technology platform, GeoVera Insurance Holdings Ltd., a residential property insurance company, and Sedgwick Inc., a provider of technology-enabled risk, benefits and integrated business solutions.
- Stephen H. Wise
-
StephenH.Wise自2010年1月起担任跨国私募股权公司凯雷集团（Carlyle Group）董事总经理，自2016年1月起担任凯雷集团（Carlyle Group）梦百合全球主管。在2006年加入凯雷之前，Wise先生曾在JLL Partners（一家位于纽约的私募股权公司）工作。任职JLL Partners公司之前，他曾任职J.W.Childs Associates公司（位于波士顿的私人股本公司），此前曾任职Credit Suisse Usoi公司的杠杆金融集团。Wise先生目前担任Albany MolecularResearch，Inc.公司（一家合同研究和药物制造组织）、CorroHealth公司（一家为梦百合公司提供商业服务的公司）、MedRisk Holdco有限责任公司（一家专注于物理治疗的工人补偿解决方案公司）、Millicent Pharma Limited公司的董事会成员，一家制药公司和Ortho-Clinical Diagnostics（用于筛选，诊断，监测和确认疾病的体外诊断解决方案的全球提供商），巴西的医院提供商Rede D’；或Sã；O Luiz S.A.，全球多线索赔管理公司Sedgwick Inc.，优化临床研究的全球健康研究网络Trinetx，Inc.，以及Welldynerx，一家独立的药房福利经理。
Stephen H. Wise has served as a member of board of directors since 2021. Mr. Wise is a Partner and Co Head of Americas Corporate Private Equity at Carlyle. Previoly, he was the Global Head of Healthcare at Carlyle. He joined Carlyle in 2006 and has led or been a key contributor to several investments including CorroHealth, Curia, Grupo Qualicorp, HCR Manorcare, Healthscope, Medline, MedRisk, Millicent Pharma, MultiPlan, OneMedical, PPD, QuidelOrtho, Rede D'Or So Luiz, Resonetics, Sedgwick, TriNetX, Unchained Labs, and llDyneRx. He has also led Carlyle's broader life sciences efforts, including the acquisition of Abingworth in 2022. Mr. Wise currently serves as a Director on the boards of Launch Therapeutics, Resonetics, Sedgwick, and Vantive. He serves on the Board of Dean's Advisors for Harvard Biness School, the Board of Dean's Advisors for the Harvard School of Public Health, and the Board of Trtees for Bucknell University. He also serves on the advisory board for the Massachetts General Hospital Center for Global Health. Prior to joining Carlyle, Mr. Wise worked with JLL Partners, a New York based private equity firm, where he foced on healthcare related investments. Previoly, he worked with J.W. Childs Associates, a Boston based private equity firm, and prior to that, in the leveraged finance group of Credit Suisse. Mr. Wise earned a B.A. in economics and finance from Bucknell University and received his M.B.A. from Harvard Biness School. - StephenH.Wise自2010年1月起担任跨国私募股权公司凯雷集团（Carlyle Group）董事总经理，自2016年1月起担任凯雷集团（Carlyle Group）梦百合全球主管。在2006年加入凯雷之前，Wise先生曾在JLL Partners（一家位于纽约的私募股权公司）工作。任职JLL Partners公司之前，他曾任职J.W.Childs Associates公司（位于波士顿的私人股本公司），此前曾任职Credit Suisse Usoi公司的杠杆金融集团。Wise先生目前担任Albany MolecularResearch，Inc.公司（一家合同研究和药物制造组织）、CorroHealth公司（一家为梦百合公司提供商业服务的公司）、MedRisk Holdco有限责任公司（一家专注于物理治疗的工人补偿解决方案公司）、Millicent Pharma Limited公司的董事会成员，一家制药公司和Ortho-Clinical Diagnostics（用于筛选，诊断，监测和确认疾病的体外诊断解决方案的全球提供商），巴西的医院提供商Rede D’；或Sã；O Luiz S.A.，全球多线索赔管理公司Sedgwick Inc.，优化临床研究的全球健康研究网络Trinetx，Inc.，以及Welldynerx，一家独立的药房福利经理。
- Stephen H. Wise has served as a member of board of directors since 2021. Mr. Wise is a Partner and Co Head of Americas Corporate Private Equity at Carlyle. Previoly, he was the Global Head of Healthcare at Carlyle. He joined Carlyle in 2006 and has led or been a key contributor to several investments including CorroHealth, Curia, Grupo Qualicorp, HCR Manorcare, Healthscope, Medline, MedRisk, Millicent Pharma, MultiPlan, OneMedical, PPD, QuidelOrtho, Rede D'Or So Luiz, Resonetics, Sedgwick, TriNetX, Unchained Labs, and llDyneRx. He has also led Carlyle's broader life sciences efforts, including the acquisition of Abingworth in 2022. Mr. Wise currently serves as a Director on the boards of Launch Therapeutics, Resonetics, Sedgwick, and Vantive. He serves on the Board of Dean's Advisors for Harvard Biness School, the Board of Dean's Advisors for the Harvard School of Public Health, and the Board of Trtees for Bucknell University. He also serves on the advisory board for the Massachetts General Hospital Center for Global Health. Prior to joining Carlyle, Mr. Wise worked with JLL Partners, a New York based private equity firm, where he foced on healthcare related investments. Previoly, he worked with J.W. Childs Associates, a Boston based private equity firm, and prior to that, in the leveraged finance group of Credit Suisse. Mr. Wise earned a B.A. in economics and finance from Bucknell University and received his M.B.A. from Harvard Biness School.
- Maria Teresa Hilado
-
Maria Teresa Hilado，担任全球制药公司Allergan plc的执行副总裁兼首席财务官（2014年12月至2018年2月退休）。在加入Allergan之前，Hilado女士从2009年到2014年担任百事可乐公司（PepsiCo Inc.）的财务高级副总裁和财务主管，负责全球运营项目，包括资本市场、资金管理、国际财务、养老金、保险以及全球采购资金。她此前曾担任Schering-Plough Corp.的副总裁兼财务主管（从2008年到2009年），也曾任职通用汽车公司（General Motors Co.）17年以上，担任领导职务，并不断增加责任，包括助理财务主管（从2006年到2008年）、GMAC Commercial Finance LLC的首席财务官（从2001年到2005年）。她的职业生涯始于菲律宾马尼拉的Far East Bank and Trust Co.。Hilado女士获得了菲律宾马尼拉雅典耀大学的管理工程学士学位和弗吉尼亚大学达顿商学院的工商管理硕士学位。
Maria Teresa Hilado served as Executive Vice President and Chief Financial Officer of Allergan plc, a global pharmaceutical company, from December 2014 until February 2018. Prior to joining Allergan, Ms. Hilado served as Senior Vice President, Finance and Treasurer of PepsiCo, Inc. from 2009 until 2014. She previoly served as Vice President and Treasurer for Schering Plough Corp. from 2008 to 2009 and spent more than 17 years with General Motors Co. in leadership roles of increasing responsibility, including Assistant Treasurer and CFO, GMAC Commercial Finance. Ms. Hilado received a bachelor's degree in management engineering from Ateneo de Manila University in the Philippines, and a master of biness administration from the Darden School of Biness at the University of Virginia. - Maria Teresa Hilado，担任全球制药公司Allergan plc的执行副总裁兼首席财务官（2014年12月至2018年2月退休）。在加入Allergan之前，Hilado女士从2009年到2014年担任百事可乐公司（PepsiCo Inc.）的财务高级副总裁和财务主管，负责全球运营项目，包括资本市场、资金管理、国际财务、养老金、保险以及全球采购资金。她此前曾担任Schering-Plough Corp.的副总裁兼财务主管（从2008年到2009年），也曾任职通用汽车公司（General Motors Co.）17年以上，担任领导职务，并不断增加责任，包括助理财务主管（从2006年到2008年）、GMAC Commercial Finance LLC的首席财务官（从2001年到2005年）。她的职业生涯始于菲律宾马尼拉的Far East Bank and Trust Co.。Hilado女士获得了菲律宾马尼拉雅典耀大学的管理工程学士学位和弗吉尼亚大学达顿商学院的工商管理硕士学位。
- Maria Teresa Hilado served as Executive Vice President and Chief Financial Officer of Allergan plc, a global pharmaceutical company, from December 2014 until February 2018. Prior to joining Allergan, Ms. Hilado served as Senior Vice President, Finance and Treasurer of PepsiCo, Inc. from 2009 until 2014. She previoly served as Vice President and Treasurer for Schering Plough Corp. from 2008 to 2009 and spent more than 17 years with General Motors Co. in leadership roles of increasing responsibility, including Assistant Treasurer and CFO, GMAC Commercial Finance. Ms. Hilado received a bachelor's degree in management engineering from Ateneo de Manila University in the Philippines, and a master of biness administration from the Darden School of Biness at the University of Virginia.
- Allen R. Thorpe
-
Allen R. Thorpe，自2008年9月起担任董事。他于1999年加入Hellman & Friedman，自2004年起担任Hellman & Friedman的常务董事。在Hellman & Friedman，他的主要涉足领域是在医疗保健和金融服务。在1999年加入Hellman & Friedman之前，他是Bain & Company的太平洋实体合伙人副总裁兼经理。 Thorpe先生是Artisan Partners Asset Management Inc., Pharmaceutical Product Development, Inc. 和Sheridan Holdings, Inc.的董事，也是Grosvenor Capital Management Holdings, LLLP的顾问董事。他早前是Mitchell International, Gartmore Investment Management Limited, Mondrian Investment Partners Ltd., Vertafore Inc., Activant Solutions和LPL Financial Holdings Inc.的董事。他获得了Stanford University的学士学位，和Harvard Business School的工商管理硕士学位。
Allen R. Thorpe,served as a director of Former MultiPlan from June 2016 through October 2020. Mr. Thorpe has served as a Partner of Hellman & Friedman LLC, a private equity firm, since January 2004 and leads the firm's New York office. Prior to joining Hellman & Friedman LLC in 1999, Mr. Thorpe was a vice president with Pacific Equity Partners in Australia, a private equity firm, and was a manager at Bain & Company, Inc., a management consulting firm. He currently serves on the board of directors of Edelman Financial Engines LLC (a private company), Medline Inc. (a private company), athenahealth (a private company), and Caliber Collision (a private company). Mr. Thorpe also previously served as Chairman of Sheridan Healthcare, Inc. (a private company), as a director of PPD, Inc. (a public company before it was acquired by Thermo Fisher in 2021), Change Healthcare Inc. (a public company before it was acquired by UnitedHealth in 2022), Mitchell International Inc. (a private company), and Artisan Partners Asset Management Inc. (a public company), as the lead independent director of LPL Financial Holdings Inc. (a public company), and a member of the advisory board of Grosvenor Capital Management Holdings, LLP (a private company), among others. - Allen R. Thorpe，自2008年9月起担任董事。他于1999年加入Hellman & Friedman，自2004年起担任Hellman & Friedman的常务董事。在Hellman & Friedman，他的主要涉足领域是在医疗保健和金融服务。在1999年加入Hellman & Friedman之前，他是Bain & Company的太平洋实体合伙人副总裁兼经理。 Thorpe先生是Artisan Partners Asset Management Inc., Pharmaceutical Product Development, Inc. 和Sheridan Holdings, Inc.的董事，也是Grosvenor Capital Management Holdings, LLLP的顾问董事。他早前是Mitchell International, Gartmore Investment Management Limited, Mondrian Investment Partners Ltd., Vertafore Inc., Activant Solutions和LPL Financial Holdings Inc.的董事。他获得了Stanford University的学士学位，和Harvard Business School的工商管理硕士学位。
- Allen R. Thorpe,served as a director of Former MultiPlan from June 2016 through October 2020. Mr. Thorpe has served as a Partner of Hellman & Friedman LLC, a private equity firm, since January 2004 and leads the firm's New York office. Prior to joining Hellman & Friedman LLC in 1999, Mr. Thorpe was a vice president with Pacific Equity Partners in Australia, a private equity firm, and was a manager at Bain & Company, Inc., a management consulting firm. He currently serves on the board of directors of Edelman Financial Engines LLC (a private company), Medline Inc. (a private company), athenahealth (a private company), and Caliber Collision (a private company). Mr. Thorpe also previously served as Chairman of Sheridan Healthcare, Inc. (a private company), as a director of PPD, Inc. (a public company before it was acquired by Thermo Fisher in 2021), Change Healthcare Inc. (a public company before it was acquired by UnitedHealth in 2022), Mitchell International Inc. (a private company), and Artisan Partners Asset Management Inc. (a public company), as the lead independent director of LPL Financial Holdings Inc. (a public company), and a member of the advisory board of Grosvenor Capital Management Holdings, LLP (a private company), among others.
- Jeffrey B. Kindler
-
Jeffrey B. Kindler，一些私人保健服务公司董事、顾问及投资者。他现任一家私营制药公司Centrexion公司的首席执行官。除了Chipotle，他还在两家其他上市公司的董事会及几个非营利组织工作过；两家上市公司是Intrexon公司（纽约证券交易所：XON）和Siga科技公司（纳克达斯全球交易市场：SIGA）。他于2010年12月从辉瑞制药公司退休，曾于此担任董事长兼首席执行官。他于2002年进入辉瑞担任高级副总裁兼总顾问，且被指派的职务职责不断提高，直到2006年被任命为首席执行官。在进入辉瑞之前，他是麦当劳公司的行政人员；且在2001年期间，他接手负责该公司的合伙品牌集团（Chipotle也包含在内）。
Jeffrey B. Kindler,2020 - Present Venture Partner, Artis Ventures, venture fund focused on life-sciences companies.2020 - Present Senior Advisor, Blackstone Group, the world's largest alternative asset manager.2013 - Present CEO, Centrexion Corporation, a biopharmaceutical company. - Jeffrey B. Kindler，一些私人保健服务公司董事、顾问及投资者。他现任一家私营制药公司Centrexion公司的首席执行官。除了Chipotle，他还在两家其他上市公司的董事会及几个非营利组织工作过；两家上市公司是Intrexon公司（纽约证券交易所：XON）和Siga科技公司（纳克达斯全球交易市场：SIGA）。他于2010年12月从辉瑞制药公司退休，曾于此担任董事长兼首席执行官。他于2002年进入辉瑞担任高级副总裁兼总顾问，且被指派的职务职责不断提高，直到2006年被任命为首席执行官。在进入辉瑞之前，他是麦当劳公司的行政人员；且在2001年期间，他接手负责该公司的合伙品牌集团（Chipotle也包含在内）。
- Jeffrey B. Kindler,2020 - Present Venture Partner, Artis Ventures, venture fund focused on life-sciences companies.2020 - Present Senior Advisor, Blackstone Group, the world's largest alternative asset manager.2013 - Present CEO, Centrexion Corporation, a biopharmaceutical company.
高管简历
中英对照 | 中文 | 英文- David Simmons
David Simmons，目前担任创新心血管医疗技术公司Cordis的董事会成员。除了担任PPD董事长外，Simmons之前的董事会服务还包括Curia Global， Inc. （Albany Molecular Research Inc.， 2021年之前），Launch Therapeutics, Inc., Medline Industries, Inc.和Owens & Minor， Inc.的任期。他目前还担任Abingworth LLP（一家领先的生命科学风险投资公司）的高级顾问。他在Carnegie Mellon大学获得应用数学和工业管理学士学位。
David Simmons,currently serves on the board of directors of Cordis, an innovative cardiovascular medical technology company. In addition to serving as Chairman of PPD, Simmons' previous board service includes tenures at Curia Global, Inc. (Albany Molecular Research Inc. prior to 2021), Launch Therapeutics, Inc., Medline Industries, Inc. and Owens & Minor, Inc. He also currently serves as a senior advisor to Abingworth LLP, a leading life sciences venture capital firm. Simmons earned his bachelor's degree in applied mathematics and industrial management from Carnegie Mellon University.- David Simmons，目前担任创新心血管医疗技术公司Cordis的董事会成员。除了担任PPD董事长外，Simmons之前的董事会服务还包括Curia Global， Inc. （Albany Molecular Research Inc.， 2021年之前），Launch Therapeutics, Inc., Medline Industries, Inc.和Owens & Minor， Inc.的任期。他目前还担任Abingworth LLP（一家领先的生命科学风险投资公司）的高级顾问。他在Carnegie Mellon大学获得应用数学和工业管理学士学位。
- David Simmons,currently serves on the board of directors of Cordis, an innovative cardiovascular medical technology company. In addition to serving as Chairman of PPD, Simmons' previous board service includes tenures at Curia Global, Inc. (Albany Molecular Research Inc. prior to 2021), Launch Therapeutics, Inc., Medline Industries, Inc. and Owens & Minor, Inc. He also currently serves as a senior advisor to Abingworth LLP, a leading life sciences venture capital firm. Simmons earned his bachelor's degree in applied mathematics and industrial management from Carnegie Mellon University.
- Christopher G. Scully
自2018年5月以来，ChristopherG.Scully一直担任我们的执行Vice President兼首席财务官，司库兼助理秘书。在加入公司之前，Scully先生在Pfizer，Inc.担任过各种职务。PFE，一家跨国制药公司，1997年至2017年，包括2014年1月至2017年8月担任Essential Health Business Unit的首席商务官，2010年10月至2014年1月担任欧洲地区总裁。
Christopher G. Scully has served as our Executive Vice President and Chief Financial Officer, Treasurer and Assistant Secretary since May 2018. Prior to joining the Company, Mr. Scully served in various roles at Pfizer, Inc. PFE, a multinational pharmaceutical corporation, from 1997 to 2017 including as their Chief Commercial Officer for the Essential Health business unit from January 2014 to August 2017 and Regional President of Europe Established Products from October 2010 to January 2014.- 自2018年5月以来，ChristopherG.Scully一直担任我们的执行Vice President兼首席财务官，司库兼助理秘书。在加入公司之前，Scully先生在Pfizer，Inc.担任过各种职务。PFE，一家跨国制药公司，1997年至2017年，包括2014年1月至2017年8月担任Essential Health Business Unit的首席商务官，2010年10月至2014年1月担任欧洲地区总裁。
- Christopher G. Scully has served as our Executive Vice President and Chief Financial Officer, Treasurer and Assistant Secretary since May 2018. Prior to joining the Company, Mr. Scully served in various roles at Pfizer, Inc. PFE, a multinational pharmaceutical corporation, from 1997 to 2017 including as their Chief Commercial Officer for the Essential Health business unit from January 2014 to August 2017 and Regional President of Europe Established Products from October 2010 to January 2014.
- Glen Donovan
Glen Donovan自2015年6月起担任公司或其前身的首席会计官。加入公司之前，Donovan从1995年11月到2015年5月在Deloitte&Touche LLP（一家跨国专业服务网络）担任多个职位，包括从2011年9月到2015年5月担任审计和保证合伙人。
Glen Donovan has served as Chief Accounting Officer of the Company or its predecessor since June 2015. Prior to joining the Company, Mr. Donovan served in various roles at Deloitte & Touche LLP, a multinational professional services network, from November 1995 to May 2015 including as Audit and Assurance Partner from September 2011 to May 2015.- Glen Donovan自2015年6月起担任公司或其前身的首席会计官。加入公司之前，Donovan从1995年11月到2015年5月在Deloitte&Touche LLP（一家跨国专业服务网络）担任多个职位，包括从2011年9月到2015年5月担任审计和保证合伙人。
- Glen Donovan has served as Chief Accounting Officer of the Company or its predecessor since June 2015. Prior to joining the Company, Mr. Donovan served in various roles at Deloitte & Touche LLP, a multinational professional services network, from November 1995 to May 2015 including as Audit and Assurance Partner from September 2011 to May 2015.
- Anshul Thakral
Anshul Thakral自2019年11月起担任我们的执行Vice President兼首席商务官。2021年2月，他还被任命为Evidera（公司的子公司）的总裁。Thakral先生曾于2016年7月至2019年11月担任公司执行Vice President兼PPD Biotech全球负责人。在加入公司之前，Thakral先生于2014年3月至2016年6月担任Gerson Lehrman Group全球生命科学业务部总经理。
Anshul Thakral has served as a member of board of directors since June 2023 until his resignation in June 2025. Mr. Thakral is Chief Executive Officer and Board Member of Launch Therapeutics, a clinical development company backed by funds managed by global investment firm Carlyle and its life sciences franchise, Abingworth. Mr. Thakral has worked for over 20 years in the pharmaceutical and biotechnology industry and is an experienced executive, management consultant and entrepreneur. Mr. Thakral was previously Chief Commercial Officer and Executive Vice President of Peri and Post-Approval Services at PPD, and prior to that was Global Head of PPD Biotech. Before PPD, Mr. Thakral ran the global life sciences business unit at Gerson Lehrman Group and worked at McKinsey & Company as an associate principal in the health care practice, where he provided strategic advice to global pharmaceutical and biotechnology companies on growth, research and development, business development and commercialization. He currently serves on the boards of TriNetX, Saama Technologies, Orsini Specialty Pharmacy, is an Operating Executive at Carlyle and is a Venture Partner at Abingworth. Mr. Thakral holds a Master's degree in Biomedical Engineering from Johns Hopkins University and a Masters Business Administration (MBA) from the Wharton School at the University of Pennsylvania.- Anshul Thakral自2019年11月起担任我们的执行Vice President兼首席商务官。2021年2月，他还被任命为Evidera（公司的子公司）的总裁。Thakral先生曾于2016年7月至2019年11月担任公司执行Vice President兼PPD Biotech全球负责人。在加入公司之前，Thakral先生于2014年3月至2016年6月担任Gerson Lehrman Group全球生命科学业务部总经理。
- Anshul Thakral has served as a member of board of directors since June 2023 until his resignation in June 2025. Mr. Thakral is Chief Executive Officer and Board Member of Launch Therapeutics, a clinical development company backed by funds managed by global investment firm Carlyle and its life sciences franchise, Abingworth. Mr. Thakral has worked for over 20 years in the pharmaceutical and biotechnology industry and is an experienced executive, management consultant and entrepreneur. Mr. Thakral was previously Chief Commercial Officer and Executive Vice President of Peri and Post-Approval Services at PPD, and prior to that was Global Head of PPD Biotech. Before PPD, Mr. Thakral ran the global life sciences business unit at Gerson Lehrman Group and worked at McKinsey & Company as an associate principal in the health care practice, where he provided strategic advice to global pharmaceutical and biotechnology companies on growth, research and development, business development and commercialization. He currently serves on the boards of TriNetX, Saama Technologies, Orsini Specialty Pharmacy, is an Operating Executive at Carlyle and is a Venture Partner at Abingworth. Mr. Thakral holds a Master's degree in Biomedical Engineering from Johns Hopkins University and a Masters Business Administration (MBA) from the Wharton School at the University of Pennsylvania.
- B. Judd Hartman
2001年7月至2021年2月，B.Judd Hartman担任该公司或其前身的总法律顾问。2017年6月，他还被任命为我们的首席行政官，并继续担任该职位。在加入该公司之前，Hartman先生从1997年到2001年担任Anker Coal Group，Inc.（一家煤矿公司）法律事务Vice President。在Anker Coal Group之前，Hartman先生是Spilman Thomas&Battle的合伙人，这是一家总部位于西弗吉尼亚州查尔斯顿的律师事务所。
B. Judd Hartman served as General Counsel of the Company or its predecessor from July 2001 to February 2021. In June 2017 he was also appointed as our Chief Administrative Officer and continues to serve in that role. Prior to joining the Company, Mr. Hartman served as Vice President of Legal Affairs for Anker Coal Group, Inc., a coal mining company, from 1997 to 2001. Prior to Anker Coal Group, Mr. Hartman was a partner with Spilman Thomas & Battle, a law firm headquartered in Charleston, West Virginia.- 2001年7月至2021年2月，B.Judd Hartman担任该公司或其前身的总法律顾问。2017年6月，他还被任命为我们的首席行政官，并继续担任该职位。在加入该公司之前，Hartman先生从1997年到2001年担任Anker Coal Group，Inc.（一家煤矿公司）法律事务Vice President。在Anker Coal Group之前，Hartman先生是Spilman Thomas&Battle的合伙人，这是一家总部位于西弗吉尼亚州查尔斯顿的律师事务所。
- B. Judd Hartman served as General Counsel of the Company or its predecessor from July 2001 to February 2021. In June 2017 he was also appointed as our Chief Administrative Officer and continues to serve in that role. Prior to joining the Company, Mr. Hartman served as Vice President of Legal Affairs for Anker Coal Group, Inc., a coal mining company, from 1997 to 2001. Prior to Anker Coal Group, Mr. Hartman was a partner with Spilman Thomas & Battle, a law firm headquartered in Charleston, West Virginia.
- Christopher Fikry
Christopher Fikry自2017年6月起担任全球实验室服务执行Vice President。在加入公司之前，Fikry博士曾于2012年9月至2017年5月在Quest Diagnostics DGX担任多个职位，包括肿瘤学和伴随诊断的Vice President兼总经理，以及Novartis AG疫苗和诊断的总经理，从2007年1月至2012年9月，包括担任战略规划总监，美国脑膜炎球菌和美国流感和旅行疫苗专营权负责人以及美国市场营销Vice President。他的职业生涯始于波士顿咨询公司（Boston Consulting Group Inc.）的梦百合实践。
Christopher Fikry has served as our Executive Vice President of Global Laboratory Services since June 2017. Prior to joining the Company, Dr. Fikry served in various roles at Quest Diagnostics DGX, from September 2012 to May 2017 including as Vice President and General Manager of Oncology and Companion Diagnostics, and at Novartis AG (NUS) Vaccines and Diagnostics, from January 2007 to September 2012 including as Director of Strategic Planning, Head of the U.S. Meningococcal and the U.S. Influenza and Travel Vaccine franchises and Vice President of U.S. Marketing. He began his career in the healthcare practice of The Boston Consulting Group Inc.- Christopher Fikry自2017年6月起担任全球实验室服务执行Vice President。在加入公司之前，Fikry博士曾于2012年9月至2017年5月在Quest Diagnostics DGX担任多个职位，包括肿瘤学和伴随诊断的Vice President兼总经理，以及Novartis AG疫苗和诊断的总经理，从2007年1月至2012年9月，包括担任战略规划总监，美国脑膜炎球菌和美国流感和旅行疫苗专营权负责人以及美国市场营销Vice President。他的职业生涯始于波士顿咨询公司（Boston Consulting Group Inc.）的梦百合实践。
- Christopher Fikry has served as our Executive Vice President of Global Laboratory Services since June 2017. Prior to joining the Company, Dr. Fikry served in various roles at Quest Diagnostics DGX, from September 2012 to May 2017 including as Vice President and General Manager of Oncology and Companion Diagnostics, and at Novartis AG (NUS) Vaccines and Diagnostics, from January 2007 to September 2012 including as Director of Strategic Planning, Head of the U.S. Meningococcal and the U.S. Influenza and Travel Vaccine franchises and Vice President of U.S. Marketing. He began his career in the healthcare practice of The Boston Consulting Group Inc.
- Ronald Garrow
Ronald Garrow自2018年7月起担任我们的执行Vice President兼首席人力资源官。加入公司之前，Garrow先生于2016年7月至2018年7月在Belk担任过各种职务，包括首席人力资源官。在加入Belk之前，Garrow先生在MasterCard Inc.工作。从2010年3月到2016年7月，他曾担任其首席人力资源官，在那里他负责开发和执行人力资源战略，以支持组织的整体业务计划和战略方向。
Ronald Garrow has served as our Executive Vice President and Chief Human Resource Officer since July 2018. Prior to joining the Company, Mr. Garrow served in various roles at Belk, from July 2016 to July 2018 including as Chief Human Resource Officer. Prior to joining Belk, Mr. Garrow worked at Mastercard Inc. MA from March 2010 to July 2016 including as its Chief Human Resource Officer, where he was responsible for developing and executing human resource strategy in support of the overall business plan and strategic direction of the organization.- Ronald Garrow自2018年7月起担任我们的执行Vice President兼首席人力资源官。加入公司之前，Garrow先生于2016年7月至2018年7月在Belk担任过各种职务，包括首席人力资源官。在加入Belk之前，Garrow先生在MasterCard Inc.工作。从2010年3月到2016年7月，他曾担任其首席人力资源官，在那里他负责开发和执行人力资源战略，以支持组织的整体业务计划和战略方向。
- Ronald Garrow has served as our Executive Vice President and Chief Human Resource Officer since July 2018. Prior to joining the Company, Mr. Garrow served in various roles at Belk, from July 2016 to July 2018 including as Chief Human Resource Officer. Prior to joining Belk, Mr. Garrow worked at Mastercard Inc. MA from March 2010 to July 2016 including as its Chief Human Resource Officer, where he was responsible for developing and executing human resource strategy in support of the overall business plan and strategic direction of the organization.
- Karen Kaucic
Karen Kaucic自2009年12月以来在该公司或其前身公司担任多个领导职位，目前担任我们的执行Vice President、首席医疗官。在加入该公司之前，Kaucic博士从2006年6月到2009年12月在AstraZeneca PLC AZN公司担任肿瘤临床开发职位。
Karen Kaucic has served in various leadership positions at the Company or its predecessor since December 2009 and currently serves as our Executive Vice President, Chief Medical Officer. Prior to joining the Company, Dr. Kaucic held positions in oncology clinical development at AstraZeneca PLC AZN from June 2006 to December 2009.- Karen Kaucic自2009年12月以来在该公司或其前身公司担任多个领导职位，目前担任我们的执行Vice President、首席医疗官。在加入该公司之前，Kaucic博士从2006年6月到2009年12月在AstraZeneca PLC AZN公司担任肿瘤临床开发职位。
- Karen Kaucic has served in various leadership positions at the Company or its predecessor since December 2009 and currently serves as our Executive Vice President, Chief Medical Officer. Prior to joining the Company, Dr. Kaucic held positions in oncology clinical development at AstraZeneca PLC AZN from June 2006 to December 2009.
- Julia James
Julia James自2021年2月起担任我们的执行Vice President，总法律顾问兼秘书。James女士于2005年加入公司，曾担任多个职位，最近于2017年6月至2021年2月担任高级副总裁，副总法律顾问，在此之前于2015年4月至2017年6月担任Vice President助理总法律顾问。加入公司之前，James从1997年2月到2005年3月在Clifford Chance LLP（一家全球领先的律师事务所）任职。
Julia James has served as our Executive Vice President, General Counsel and Secretary since February 2021. Ms. James joined the Company in 2005 and has served in various roles, most recently as Senior Vice President, Deputy General Counsel from June 2017 to February 2021 and prior to that as Vice President, Assistant General Counsel from April 2015 to June 2017. Prior to joining the Company, Ms. James worked at Clifford Chance LLP, a leading global law firm, from February 1997 to March 2005.- Julia James自2021年2月起担任我们的执行Vice President，总法律顾问兼秘书。James女士于2005年加入公司，曾担任多个职位，最近于2017年6月至2021年2月担任高级副总裁，副总法律顾问，在此之前于2015年4月至2017年6月担任Vice President助理总法律顾问。加入公司之前，James从1997年2月到2005年3月在Clifford Chance LLP（一家全球领先的律师事务所）任职。
- Julia James has served as our Executive Vice President, General Counsel and Secretary since February 2021. Ms. James joined the Company in 2005 and has served in various roles, most recently as Senior Vice President, Deputy General Counsel from June 2017 to February 2021 and prior to that as Vice President, Assistant General Counsel from April 2015 to June 2017. Prior to joining the Company, Ms. James worked at Clifford Chance LLP, a leading global law firm, from February 1997 to March 2005.
- William J. Sharbaugh
William J. Sharbaugh，本公司的首席运营官。2007年5月加入PPD之前，他在Bristol-Myers Squibb工作了6年，最后的职务是全球开发业务副总裁，任期2005-2007，负责55个国家临床业务的战略指导。2001-2005，他担任全球临床供应业务执行总监，负责全球调查产品的规划、制造、包装、分发。加入Bristol-Myers Squibb之前，他在Merck and Co.工作了10年，担任过临床供应运营、销售、制造方面的各种职务。
William J. Sharbaugh has served as Chief Operating Officer of the Company or its predecessor since May 2007. Prior to joining the Company, Mr. Sharbaugh served in various roles at Bristol-Myers Squibb BMY, a multinational pharmaceutical corporation, from 2001 to 2007 most recently as their Vice President of Global Development Operations. Prior to Bristol-Myers Squibb, Mr. Sharbaugh served in various roles in research and development, manufacturing, quality assurance and sales at Merck & Co. (MRK), a multinational pharmaceutical corporation, from 1991 to 2001.- William J. Sharbaugh，本公司的首席运营官。2007年5月加入PPD之前，他在Bristol-Myers Squibb工作了6年，最后的职务是全球开发业务副总裁，任期2005-2007，负责55个国家临床业务的战略指导。2001-2005，他担任全球临床供应业务执行总监，负责全球调查产品的规划、制造、包装、分发。加入Bristol-Myers Squibb之前，他在Merck and Co.工作了10年，担任过临床供应运营、销售、制造方面的各种职务。
- William J. Sharbaugh has served as Chief Operating Officer of the Company or its predecessor since May 2007. Prior to joining the Company, Mr. Sharbaugh served in various roles at Bristol-Myers Squibb BMY, a multinational pharmaceutical corporation, from 2001 to 2007 most recently as their Vice President of Global Development Operations. Prior to Bristol-Myers Squibb, Mr. Sharbaugh served in various roles in research and development, manufacturing, quality assurance and sales at Merck & Co. (MRK), a multinational pharmaceutical corporation, from 1991 to 2001.
- 姜大卫
姜大卫自2016年10月起担任我们的全球临床开发执行副总裁。2013年7月至2016年9月，Johnston博士担任PPD实验室执行副总裁兼全球负责人。在加入公司之前，Johnston博士于1998年4月至2013年6月在Laboratory Corp of America LH工作，最近担任高级副总裁兼临床试验业务全球负责人。
David Johnston has served as Executive Vice President of Global Clinical Development since October 2016. From July 2013 to September 2016 Dr. Johnston served as Executive Vice President and Global Head of PPD Laboratories. Prior to joining the Company, Dr. Johnston worked at Laboratory Corp of America LH from April 1998 to June 2013 where he most recently served as Senior Vice President and Global Head of the Clinical Trials business.- 姜大卫自2016年10月起担任我们的全球临床开发执行副总裁。2013年7月至2016年9月，Johnston博士担任PPD实验室执行副总裁兼全球负责人。在加入公司之前，Johnston博士于1998年4月至2013年6月在Laboratory Corp of America LH工作，最近担任高级副总裁兼临床试验业务全球负责人。
- David Johnston has served as Executive Vice President of Global Clinical Development since October 2016. From July 2013 to September 2016 Dr. Johnston served as Executive Vice President and Global Head of PPD Laboratories. Prior to joining the Company, Dr. Johnston worked at Laboratory Corp of America LH from April 1998 to June 2013 where he most recently served as Senior Vice President and Global Head of the Clinical Trials business.